S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Investors Look to Capitalize on the Budding Green Revolution (Ad)
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Investors Look to Capitalize on the Budding Green Revolution (Ad)
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Investors Look to Capitalize on the Budding Green Revolution (Ad)
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Investors Look to Capitalize on the Budding Green Revolution (Ad)
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
NASDAQ:OGI

OrganiGram - OGI Stock Forecast, Price & News

$1.13
+0.04 (+3.67%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.08
$1.14
50-Day Range
$0.92
$1.19
52-Week Range
$0.90
$2.92
Volume
1.40 million shs
Average Volume
2.43 million shs
Market Capitalization
$354.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.05

OrganiGram MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
169.9% Upside
$3.05 Price Target
Short Interest
Healthy
3.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of OrganiGram in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.09) to ($0.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

731st out of 1,108 stocks

Pharmaceutical Preparations Industry

369th out of 542 stocks

OGI stock logo

About OrganiGram (NASDAQ:OGI) Stock

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on OGI shares. Stifel Nicolaus dropped their price target on shares of OrganiGram from C$2.25 to C$1.50 in a research note on Friday, July 15th. Atb Cap Markets raised shares of OrganiGram from a "sector perform" rating to an "outperform" rating in a research note on Tuesday, April 12th. Finally, Alliance Global Partners reduced their price objective on shares of OrganiGram from C$2.25 to C$1.50 in a research note on Friday, July 15th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $3.04.

OrganiGram Stock Up 2.8 %

Shares of NASDAQ:OGI traded up $0.03 during trading on Wednesday, reaching $1.12. The stock had a trading volume of 67,981 shares, compared to its average volume of 4,437,495. OrganiGram has a 52 week low of $0.90 and a 52 week high of $2.92. The firm has a market capitalization of $351.35 million, a price-to-earnings ratio of -12.11 and a beta of 0.62. The stock has a fifty day simple moving average of $1.04 and a two-hundred day simple moving average of $1.32.

Receive OGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OrganiGram and its competitors with MarketBeat's FREE daily newsletter.

OGI Stock News Headlines

Why OrganiGram Holdings Shares Rose 20.9% This Week
Here's Why OrganiGram Shares Are Rising
See More Headlines
Receive OGI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OrganiGram and its competitors with MarketBeat's FREE daily newsletter.

OGI Company Calendar

Last Earnings
7/12/2021
Today
8/11/2022
Fiscal Year End
8/31/2022
Next Earnings (Estimated)
11/22/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OGI
Fax
N/A
Employees
841
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.05
High Stock Price Forecast
$5.30
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+169.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-103,090,000.00
Pretax Margin
-28.91%

Debt

Sales & Book Value

Annual Sales
$62.43 million
Book Value
$1.26 per share

Miscellaneous

Free Float
N/A
Market Cap
$354.49 million
Optionable
Not Optionable
Beta
0.62

Key Executives

  • Mr. Derrick W. West CPA (Age 55)
    CPA, (CA), Chief Financial Officer
    Comp: $244.82k
  • Ms. Helen Martin (Age 44)
    Chief Legal Officer & Corp. Sec.
    Comp: $229.3k
  • Mr. Gregory Engel (Age 57)
    Special Advisor
    Comp: $458.69k
  • Mr. Timothy Emberg
    Chief Revenue Officer
  • Mr. Paolo De Luca C.A. (Age 49)
    C.F.A, Chief Strategy Officer
    Comp: $241.58k
  • Ms. Beena G. Goldenberg (Age 59)
    CEO & Director
  • Ms. Nathalie Batten
    VP of Operations
  • Amy Schwalm
    VP of Investor Relations
  • Ms. Megan Amber McCrae
    Sr. VP of Marketing & Communications
  • Tina Shannon
    VP of HR













OGI Stock - Frequently Asked Questions

Should I buy or sell OrganiGram stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OGI shares.
View OGI analyst ratings
or view top-rated stocks.

What is OrganiGram's stock price forecast for 2022?

6 equities research analysts have issued twelve-month price targets for OrganiGram's stock. Their OGI share price forecasts range from $1.50 to $5.30. On average, they expect the company's share price to reach $3.05 in the next twelve months. This suggests a possible upside of 169.9% from the stock's current price.
View analysts price targets for OGI
or view top-rated stocks among Wall Street analysts.

How have OGI shares performed in 2022?

OrganiGram's stock was trading at $1.75 at the beginning of the year. Since then, OGI shares have decreased by 35.4% and is now trading at $1.13.
View the best growth stocks for 2022 here
.

When is OrganiGram's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 22nd 2022.
View our OGI earnings forecast
.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) announced its quarterly earnings results on Monday, July, 12th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $16.55 million for the quarter, compared to analysts' expectations of $13.95 million. OrganiGram had a negative net margin of 27.78% and a negative trailing twelve-month return on equity of 11.81%.

What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), Auxly Cannabis Group (CBWTF), Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), CNBX Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by a variety of institutional and retail investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (1.24%), Merlin Capital LLC (0.67%), Swiss National Bank (0.20%), Connor Clark & Lunn Investment Management Ltd. (0.18%), AdvisorShares Investments LLC (0.13%) and TD Asset Management Inc. (0.07%).

How do I buy shares of OrganiGram?

Shares of OGI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $1.13.

How much money does OrganiGram make?

OrganiGram (NASDAQ:OGI) has a market capitalization of $354.49 million and generates $62.43 million in revenue each year. The company earns $-103,090,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does OrganiGram have?

The company employs 841 workers across the globe.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The official website for the company is www.organigram.ca. The company can be reached via phone at (844) 644-4726.

This page (NASDAQ:OGI) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.